Effective measures for controlling trypanosomiasis

Bibliography

• MOLYNEUX DH: Current public health status of trypanosomiasis and Leishmaniasis. In: Trypanosomiasis, and leishmaniasis: biology and control. G Hide, JC Mottram, GH Coombs, DH Holmes (Eds), CAB International, Oxon, UK (1997):39–50.
   Google Scholar
• KRISTJANSON PM, SWALLOW BM, ROWLAND GJ et al.: Measuring the costs of African animal trypanosomiasis, the potential benefits of control and returns and research. Agr. Sys. (1999) 59:79–98.
   Web of Science ®Google Scholar
• CROFT SL: The current status of antiparasitic chemotherapy. Parasitology (1997) 114:S3–S25.
   Web of Science ®Google Scholar
• ROSS CA, SUTHERLAND DV: Drug resistance in trypanosomatids. In: Trypanosomiasis, and leishmaniasis: biology and control. G Hide, JC Mottram, GH Coombs, DH Holmes (Eds), CAB International, Oxon, UK (1997):259–269.
   Google Scholar
• BARRET MP: The fall and rise of sleeping sickness. Lancet (1999) 353:1113–1114.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON M, CALLEUS M, KUNZT D et al.: Synthesis and activity of inhibitors highly specific for glycolytic enzymes from T brucei. Mol Biochem. Parasitol (1993) 59:201–210.
   PubMed Web of Science ®Google Scholar
• HUNTER WN: A structure based approach to drug discovery; crystallography and implications for the development of antiparasitic drugs. Parasitology (1997) 114:S17–S29.
   Web of Science ®Google Scholar
• WANG CC: Validating targets for antiparasitic chemotherapy. Parasitology (1997) 114:S31–544.
   PubMed Web of Science ®Google Scholar
• DENISE H, BARRET MP: Uptake and mode of action of drugs used against sleeping sickness. Biochem. Pharmacol (2001) 61:1–5.
   PubMed Web of Science ®Google Scholar
• PEPIN J, MILORD F: The treatment of human African trypanosomiasis. Adv. Parasitology (1994) 33:1–47.
   PubMed Web of Science ®Google Scholar
• KEISER J, ERICSSON O, BURRI C: Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin. Pharm. Terap. (2000) 67:478–488.
   PubMed Web of Science ®Google Scholar
• HARDER A. GREIF G, HABERKORN A: Chemotherapeutic approaches to protozoa: kinetoplastida- current knowledge and outlook. Parasitology Res. (2000) 87:778–780.
   Web of Science ®Google Scholar
• ERICSSON O, SCHWEDA E, BRONNER V et al.: Determination of melarsoprol in biological fluids by high performance liquid chromatography and characterization of stereoisomers by nuclear magnetic resonance spectroscopy./ Chrom. B. Biomed. Sci. App. (1997) 690:243–251.
   PubMed Web of Science ®Google Scholar
• SCHMID C, NKUNKU S, MEROLLE A et al.: Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet (2004) 364(9436):789–790.
   PubMed Web of Science ®Google Scholar
• BOUTEILLE B, OUKEM O, BISSER S et al.: Treatment perspectives for human African trypanosomiasis. Fundamentals Clin. PharmacoL (200) 17:171–181.
   Google Scholar
• BARRETT MP: Problems for the chemotherapy of human African trypanosomiasis. Curr. Opin. Infect. Dis. (2000) 13:647–651.
   PubMed Web of Science ®Google Scholar
• NKANGA NG, MUTOMBO L, KAZIDI K et al.: Neuropathies arsenicals apres traitement de la trypanosomiase humaine au melarsoprol. Med. Aft. Noire (1988) 35:73–76
   Google Scholar
• BLUM J, NKUNKU S, BURRI C: Clinical description of encephalopathic syndrome and risk factors for their occurrence and outcome durin melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health (2001) 6:390–400.
   PubMed Web of Science ®Google Scholar
• APTED Fl: Four years experience of melarsen oxide/BAL in the treatment of late stage Rhodesian sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. (1957):75–86.
   PubMedGoogle Scholar
• BURRI C, KEISER J: Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop. Med. Int. Health (2001) 6:412–420.
   PubMed Web of Science ®Google Scholar
• LEGROS D, EVANS S, MAISO F et aL: Risk factors for the treatment failures after melarsoprol for T b. gambiense trypanosomiasis in Uganda. Tran. Roy. Soc. Trop. Med. Hyg. (1999) 93:439–442.
   PubMed Web of Science ®Google Scholar
• BURRI C, NKUNKU S, MEROLLE A et aL: Efficacy of a new, concise schedule for melarsoprol in treatment of sleeping sickness caused by T b. gambiense: a randomised trial. Lancet (2000) 355:1419–1425.
   PubMed Web of Science ®Google Scholar
• MATOVU E, ENYARU JC, SCHMID C et aL: Melarsoprol refractory Tb. gambiense from Omugo, north western Uganda. Trop. Med. Int. Health (2001) 6:497–411.
   Web of Science ®Google Scholar
• CATER NS, FAIRLAMB AH: Arsenicalresistant trypanosome lack the unusual adenosine transporter. Nature (1993) 361:173–175.
   PubMed Web of Science ®Google Scholar
• BARRET MP, FAIRLAMB AH: The biochemical basis of arsenical-diamidine cross resistance in African trypanosomes. ParasitoLlbday (1999) 15:136–140.
   Web of Science ®Google Scholar
• SANDS M, KRON MA, BROWN RB: Pentamidine, a review. Rev. Inf Dis (1985) 7:625–634.
   PubMedGoogle Scholar
• DAMPER D, PATTON CL: Pentamidine transport and sensitivity in brucei group trypanosomes. J. ProtozooL (1976) 23:349–356.
   PubMedGoogle Scholar
• CATER NS, BERGER BJ, FAIRLAMB AH: Uptake of diaimine drugs by the P2 nucleoside transporter in melarsen sensitive and resistant T brucei. Biol. Chem. (1995). 270:28153–28157.
   Web of Science ®Google Scholar
• SCOTT AG, TAIT A, TURNER CM: T brucei lack of cross-resistance to melarsoprol in vitro by Cymelarsen-resistant parasites. Exp. ParasitoL (1996) 86:181–190.
   Web of Science ®Google Scholar
• NUN CM, NEIDE S: Sequence dependent drug binding to the minor groove of DNA crystal structure of DNA dodecamer d(cgcaaatttgcg)2 complexed with propamidine. J. Med. Chem. (1995) 38:2317–2325.
   PubMed Web of Science ®Google Scholar
• SHAPIRO TA: Inhibition of topoisomerases in African trypanosomes. Acta Trop. (1993) 54:251–260.
   PubMed Web of Science ®Google Scholar
• BITONTI AJ, DUMONT JA, McCANN PP: Characterization of T b. brucei 5-adenosyl methionine decarboxylase and its inhibition by berenil, pentamidine, methylglyoxal (bis guynylhydrazone). Biochem. J. (1986) 237:685–689.
   Google Scholar
• WOOD DH, HALL JE, ROSE BG et aL: 1,5-Bis-(amidinophenoxypentane) pentamidine is a potent inhibitor of H3-diazoxan binding to imidazole 12 binding sites. Eur. j PharmacoL (1998) 353:97–103.
   PubMed Web of Science ®Google Scholar
• HAWKING F: Concentration of Bayer 205 (Germanin) in human blood and cerebrospinal fluid after treatment. Trans. R. Soc. Trop. Med. Hyg. (1940) 34:37–52.
   Google Scholar
• COLLINS JM, KLECKER RW, YARCHOAN R et aL: Clinical pharmacokinetics of suramin inpatients with HTLV-III/LAV infection. Clin. Pharm. (1986) 26:22–26.
   Google Scholar
• VANSTERKENURG EL, COPPENS I, WILTING J et aL: The uptake of trypanocidal drug suramin in combination with LDL by T brucei and its possible mode of action. Acta Trop. (1993) 54:237–250.
   PubMed Web of Science ®Google Scholar
• MAHLEY RW, INNERARITY TL, PITAS RE et aL: Inhibition of the lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in B apoproteins. j Biol. Chem. (1977) 252:7279–7287.
   PubMed Web of Science ®Google Scholar
• HAWKING F. Suramin with special reference to onchocerciasis. Adv. PharmacoLChemother. (1978) 15:289–322.
   PubMedGoogle Scholar
• WILLIAMSON J: Review of chemotherapeutic agents. In: The African trypanosomioases. HW Mulligan (Ed.), George Allen and Unwin, London, UK (1970):125–221.
   Google Scholar
• DIXON H, GINGER CD, WILLAIMSON J: The lipid metabolism of blood and culture forms of T lewisi and T rhodesiense. Comp. Biochem. PhysioL (1971) 39B:247–266.
   Google Scholar
• DE KONING HD: Transporters in African trypanosomes: role in drug action and resistance. Int. J. ParasitoL (2001) 31:512–522.
   PubMed Web of Science ®Google Scholar
• SCOTT AG, TAIT A, TURNER CM: Characterization of cloned lines of T brucei expressing stable resistance to MelCy and suramin. Acta Trop. (1996) 60:251–262.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Suramin: a potent inhibitor of reverse transcriptase of RNA tumor viruses. Cancer Lett. (1979) 8:9–22.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND IA, PEREGRINE AS, LONSDALE-ECCLES JD et aL: Transport of isometamidium (samorin) by drug resistant and drug-sensitive T congolense. Parasitology (1991) 103:245–251
   PubMedGoogle Scholar
• SUTHERLAND IA, MOUNSEY A. HOLMES PH: Reduced accumulation of isometamidium by drug resistant T congolense. Parasitology (1992) 104:461–467.
   PubMedGoogle Scholar
• MCCANN PP, PEGG AE: Ornithine decarboxylase as an enzyme target for therapy. PharmacoL Ther. (1992) 54:195–215.
   PubMed Web of Science ®Google Scholar
• BARRET SV, BARRET MP: Anti-sleeping sickness drugs and cancer chemogtherapy. Parasitology Today (2000) 16:7–9.
   PubMedGoogle Scholar
• PEPIN J, MILORD F: The treatment of human African trypanosomiasis. Adv. ParasitoL (1994) 33:1–47.
   PubMed Web of Science ®Google Scholar
• BITONTI AJ, BACCHI CJ, McCANN PP et aL: Uptake of difluoromethylornithine by Trypanosoma brucei brucei. Biochem. PharmacoL (1986) 35:351–354.
   PubMed Web of Science ®Google Scholar
• PHILLIPS MA, WANG CC: Trypanosoma brucei brucei mutant resistant to a-difluoromethylornithine. MoL Biochem. ParasitoL (1987) 22:9–17.
   PubMed Web of Science ®Google Scholar
• GHODA L, PHILPIPS MA, BASS KE et aL: Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. J. BioL Chem (1990) 265:11823–11826.
   PubMed Web of Science ®Google Scholar
• ITEN M, METT H, EVANS A et ell.: Alteration in ornithine decarboxylase characteristics accounts for tolerance of Trypanosoma brucei rhodesiense to D,L-difluoromethylornithine. Antimicrob. Agents Chemother. (1997) 41:1922–1925.
   Google Scholar
• VAN NIEUWENHOE S, DECLERQ V: Nifurtimox therapy in late stage arsenical refractory gambiense sleping sickness in. Proceedings of 17th MeetingISCTRC Arusha. OAU/STRC, Nairobi, Kenya (1989):264.
   Google Scholar
• TOWNSON SM, BOREHAM PL, UPCROFT P et aL: Resistance to nitroheterocyclic drugs. Acta Trop. (1994) 56:125–141.
   PubMed Web of Science ®Google Scholar
• FAIRLAMB AH: Future prospects for the chemotherapy of human trypanosomiasis 1. Novel approaches to the chemotherapy of trypanosoiasis. Trans. R. Soc. Trop. Med. Hyg. (1990) 84:613–617.
   PubMedGoogle Scholar
• FAIRLAMB AH: Trypanothione metabolism and rational approach to drug design. Biochem. Soc. Trans. (1990) 18:717–720.
   PubMed Web of Science ®Google Scholar
• DUHM B, MAUL W, MEDENWALD P: Investigations on Pharmacokinetics of nifurtimox- 35 S in rat and dog. Arzneimittelfirschung (1972) 22: 1617-1624.
   Google Scholar
• VAN NIEUWENHOE S, DECLERQ J: Nifurtimox (lampit) treatment in late stage of gambiense sleeping sickness. In: Proceedings 17th Meeting ISCTRC Arusha. OAU/STRC, Nairobi, Kenya (1981):206.
   Google Scholar
• VAN NIEUWENHOE S: Advances in sleeping sickness therapy (1992) 72:39–51.
   Google Scholar
• MOENS F, DE WILDE M, NGATO K: Traitement au nifurtimox de la trypanossomiase humaine africaine. Ann. Soc. Beige. Med. Trop. (1984) 64:37–43.
   PubMedGoogle Scholar
• MONTALTO D, MECCA M, DIAZ EG, CAATRO JA: Nifurtimox biotransformation to reactive metabolites or nitrites in liver fractions and odel systems. ToxicoL Lett. (2002) 15:1–8.
   Google Scholar
• JENNINGS FW: Combination therapy of CNS trypanosomiasis. Acta Trop. (1993) 54:205–213.
   PubMed Web of Science ®Google Scholar
• ENANGA B, NDONG JM, BONDRA H et aL: Pharmacokinetics, metabolism and excreation of megazol in Tb gambiense primate model human African trypanosomiasis. Arzneimittelfirschung (2000) 50:158–162.
   PubMed Web of Science ®Google Scholar
• KEISER J, BURRI C: Physicochemical properties of the trypanocidal drug melarsoprol. Acta Trop. (2000) 74:101–104.
   PubMed Web of Science ®Google Scholar
• ATAWODI SE, IBARHIM S, AMEH D et al.: Indigenous knowledge system for treatment of trypanosomiasis in kaduna state of Nigeria. J. Ethnopharmaca (2002) 79:279–282.
   PubMed Web of Science ®Google Scholar
• NOK AJ, ESIEVO KA, LONGDET I et al.: Trypanocidal potentials of Azadirachta indica: in vivo activity of leaf extract against Trypanosoma brucei. J. Clin. Biochem. Nutr. (1993)15:113–118.
   Web of Science ®Google Scholar
• NOK AJ, -WILLIAMS S, ONYENEKWE PC: Allium sativa induced death of African trypanosomes. ParasitoL Res. (1996) 82:634–637.
   PubMed Web of Science ®Google Scholar
• NOK AJ: Azaanthraquinone inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma congolense. Cell Biochem. Func. (2001) 19:1–8.
   PubMedGoogle Scholar
• FREIBURGHAUS F, OGWAL EN, NKUNYA MH et aL: In vitro antitrypanosomal activity of African plants used in traditional medicine in Uganda to treat sleeping sickness. Trop. Med. Int. Health (1996) 1(6):765–771.
   PubMed Web of Science ®Google Scholar
• ATINDEJOU KK, SCHMID C, BRUN R et aL: Antitrypanosomal and antiplasmodial activity of medicinal plants from Cote d'Ivoire. J. EthnopharmacoL (2004) 90:221–227.
   PubMed Web of Science ®Google Scholar
• HONDA G, TABATA M: Isolation of antifitngal principle tryptanthrin, from Strobilanthes cusia. Planta Med. (1979) 36:85–90.
   PubMed Web of Science ®Google Scholar
• SCOVILL J, BLANK E KONNICK M et aL: Antitrypanosomal activities of tryptanthrin. Anti microb. Agents Chemother. (2002) 46:882–883
   PubMed Web of Science ®Google Scholar
• HAINES LR, HANCOCK RE, PEARSON TW: Cationic antimicrobial peptide killing of African trypanosomes and Sodalis glossinidius, a bacterial symbiont of the insect vector of sleeping sickness. Vector-borne Zoonotic Diseases (2003) 3:175–186.
   PubMed Web of Science ®Google Scholar
• LINGER M, ACOSTA-SERRANO A. VAN DEN ABBEELE J et aL: Cleavage of trypanosome surface glycoproteins by alkaline trypsin-like enzyme(s) in the mid gut of Glossina morsitans. Int. J. Parasitol. (2003) 33:1319-1328.
   Google Scholar